Molecular Target Synopsis
Overview
Domains and Structures
Drugs and Clinical Candidates
Druggability
Chemistry
Ligand Efficiency Plot
Pathways
Family Cladogram
Interaction Network
Gene Expression
Gene Copy Number Variation
RNAi
Mutations
Germline Genetics

RPRD1A (Q96P16) - Domains And Structures - Molecular Target Synopsis

Click Here to View Molecular Target 3D Synopsis

Select a homology cutoff:
Structural Sequence Similarity Matches
Domains Covered Gene Name (Uniprot) Solved in Complex with Organism PDB Chain Identity E-Value Resolution Ligands Release Date
Cell-cycle alteration and expression-elevated protein in tumour (87%) (view alignment) RPRD1B (Q9NQG5) - HUMAN 4FLA_A 70.99 5.0E-39 2.2Å - 2012-08-22
RNA polymerase II-binding domain. (100%) (view alignment) RPRD1B (Q9NQG5) - HUMAN 4Q96_B 72.39 3.0E-53 1.848Å - 2014-06-04
RNA polymerase II-binding domain. (100%) (view alignment) RPRD1B (Q9NQG5) - HUMAN 4Q94_A 72.39 3.0E-53 1.85Å - 2014-06-18
RNA polymerase II-binding domain. (100%) (view alignment) RPRD1B (Q9NQG5) - HUMAN 4HFG_A 72.39 3.0E-53 2Å - 2012-10-17
RNA polymerase II-binding domain. (100%) (view alignment) RPRD1B (Q9NQG5) - HUMAN 4Q96_A 72.39 3.0E-53 1.848Å - 2014-06-04
RNA polymerase II-binding domain. (100%) (view alignment) RPRD1A (Q96P16) POLR2A (P24928) HUMAN 4JXT_A 100 0 1.9Å - 2013-11-13
RNA polymerase II-binding domain. (100%) (view alignment) RPRD2 (Q5VT52) - HUMAN 4FLB_A 38.13 1.0E-19 1.8Å - 2012-08-15
Cell-cycle alteration and expression-elevated protein in tumour (87%) (view alignment) RPRD1B (Q9NQG5) - HUMAN 4FLA_C 70.99 5.0E-39 2.2Å - 2012-08-22
RNA polymerase II-binding domain. (100%) (view alignment) RPRD1B (Q9NQG5) - HUMAN 4FU3_B 73.13 6.0E-54 1.9Å - 2012-08-29
Cell-cycle alteration and expression-elevated protein in tumour (87%) (view alignment) RPRD1B (Q9NQG5) - HUMAN 4FLA_D 70.99 5.0E-39 2.2Å - 2012-08-22
RNA polymerase II-binding domain. (100%) (view alignment) RPRD1B (Q9NQG5) - HUMAN 4Q96_E 72.39 3.0E-53 1.848Å - 2014-06-04
RNA polymerase II-binding domain. (100%) (view alignment) RPRD1B (Q9NQG5) - HUMAN 4Q94_B 72.39 3.0E-53 1.85Å - 2014-06-18
RNA polymerase II-binding domain. (100%) (view alignment) RPRD1A (Q96P16) - HUMAN 4NAC_B 100 0 2Å - 2013-12-11
RNA polymerase II-binding domain. (100%) (view alignment) RPRD1B (Q9NQG5) - HUMAN 4HFG_B 72.39 3.0E-53 2Å - 2012-10-17
RNA polymerase II-binding domain. (100%) (view alignment) RPRD1A (Q96P16) - HUMAN 4NAC_A 100 0 2Å - 2013-12-11
Cell-cycle alteration and expression-elevated protein in tumour (100%) (view alignment) RPRD1B (Q9NQG5) - HUMAN 4NAD_B 70 8.0E-47 2.8Å - 2013-12-11
RNA polymerase II-binding domain. (100%) (view alignment) RPRD1B (Q9NQG5) - HUMAN 4Q96_D 72.39 3.0E-53 1.848Å - 2014-06-04
Cell-cycle alteration and expression-elevated protein in tumour (87%) (view alignment) RPRD1B (Q9NQG5) - HUMAN 4FLA_B 70.99 5.0E-39 2.2Å - 2012-08-22
RNA polymerase II-binding domain. (100%) (view alignment) RPRD1B (Q9NQG5) - HUMAN 4FU3_A 73.13 6.0E-54 1.9Å - 2012-08-29
Cell-cycle alteration and expression-elevated protein in tumour (100%) (view alignment) RPRD1B (Q9NQG5) - HUMAN 4NAD_A 70 8.0E-47 2.8Å - 2013-12-11